Draupnir Bio Raises €12M for Protein Degradation Tech and Expansion

Draupnir Bio raises €12M in Seed Funding

Draupnir Bio (Linkedin), a biotechnology company based in Copenhagen, Denmark, has secured €12M in seed funding. With a focus on targeted protein degradation, they are poised to revolutionize the treatment of historically challenging diseases.

Funding Amount: €12 million

Industry: Biotechnology Research

Employee Count: 11-50

CEO: Andrew Hotchkiss (CEO Linkedin)

What Draupnir Bio needs to buy: Draupnir Bio is seeking partnerships with research organizations, contract research organizations (CROs), manufacturers, suppliers, and regulatory consultants. These collaborations will support the further development of their preclinical pipeline, production and distribution of their oral, small molecule degraders, and navigating the complex regulatory landscape in the biotechnology and pharmaceutical industries. Companies specializing in research, manufacturing, and regulatory expertise are ideal partners for Draupnir Bio's innovative approach to targeted protein degradation therapies.